Escitalopram ( DrugBank: Escitalopram )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
6	パーキンソン病	4
13	多発性硬化症／視神経脊髄炎	2
46	悪性関節リウマチ	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00965497 (ClinicalTrials.gov)	July 2009	7/8/2009	Escitalopram (Lexapro) for Depression MS or ALS	An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis	Major Depression;Multiple Sclerosis;Amyotrophic Lateral Sclerosis	Drug: escitalopram	University of South Carolina	NULL	Completed	18 Years	70 Years	All	13	Phase 3	United States

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03652870 (ClinicalTrials.gov)	October 31, 2019	8/8/2018	Antidepressants Trial in Parkinson's Disease	A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease	Depression;Parkinson Disease	Drug: Nortriptyline;Drug: Escitalopram;Drug: Placebo	University College, London	London North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS Lothian	Recruiting	18 Years	85 Years	All	408	Phase 3	United Kingdom
2	EUCTR2018-002942-35-GB (EUCTR)	31/10/2019	05/09/2019	A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo, and standard psychological care, for depression in Parkinson’s disease	A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo and standard psychological care for depression in Parkinson’s Disease - Antidepressants Trial in Parkinson's Disease (ADepT-PD)	Depression in Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10012378;Term: Depression;System Organ Class: 10037175 - Psychiatric disorders MedDRA version: 20.0;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Escitalopram INN or Proposed INN: Escitalopram oxalate Trade Name: Nortriptyline Product Name: Nortriptyline INN or Proposed INN: Nortriptyline hydrochloride	University College London Comprehensive Clinical Trials Unit	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	408	Phase 3	United Kingdom
3	EUCTR2007-004009-93-IT (EUCTR)	20/05/2008	14/07/2008	Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram	Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram	Depression, anxiety and ICD MedDRA version: 14.1;Level: SOC;Classification code 10037175;Term: Psychiatric disorders;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: CIPRALEX INN or Proposed INN: Escitalopram Trade Name: CIPRALEX INN or Proposed INN: Escitalopram	LUNDBECK ITALIA	NULL	Not Recruiting			Female: yes Male: yes			Italy
4	NCT00070941 (ClinicalTrials.gov)	July 2003	9/10/2003	SAM-e for the Treatment of Depression in Patients With Parkinson's Disease	SAM-e Treatment of Depression in Parkinson's Disease.	Parkinson's Disease;Depression	Drug: SAM-e;Drug: oral escitalopram;Drug: placebo	New York University School of Medicine	National Center for Complementary and Integrative Health (NCCIH);Office of Dietary Supplements (ODS)	Completed	30 Years	80 Years	All	29	Phase 2/Phase 3	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00965497 (ClinicalTrials.gov)	July 2009	7/8/2009	Escitalopram (Lexapro) for Depression MS or ALS	An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis	Major Depression;Multiple Sclerosis;Amyotrophic Lateral Sclerosis	Drug: escitalopram	University of South Carolina	NULL	Completed	18 Years	70 Years	All	13	Phase 3	United States
2	NCT00151294 (ClinicalTrials.gov)	November 2004	6/9/2005	The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis	A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis	Depression;Multiple Sclerosis	Drug: escitalopram oxalate antidepressant	Weill Medical College of Cornell University	Forest Laboratories	Terminated	18 Years	N/A	Both	20	Phase 4	United States

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05480878 (ClinicalTrials.gov)	December 2, 2022	23/7/2022	Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis	Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo;Drug: Nitazoxanide 500Mg Oral Tablet;Drug: Escitalopram 10mg	Tanta University	NULL	Not yet recruiting	18 Years	75 Years	All	90	Phase 3	NULL

先頭へ